The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

An AI researcher and former teacher shares insights on how new technologies will affect math instruction and learning.

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

We recently published a list of Jim Cramer Looked At These 23 Stocks Recently. In this article, we are going to take a look ...

BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...